CMS Colorectal Cancer Drug Coverage Decision Comments Are Due Dec. 31
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin, Erbitux, Eloxatin and Camptosar clinical trials in off-label uses would be funded under the agency's draft coverage determination. Comments on CMS' draft Medicare drug benefit documents and applications for FDA's continuous marketing Pilot 2 program are also due the last week of December.